Hua Xia Shi Bao·2025-11-08 02:57Core Insights - The article highlights the significant growth and transformation of multinational pharmaceutical companies in China over the past eight years, particularly through their participation in the China International Import Expo (CIIE) [11] - Companies like Roche and Gilead are expanding their product offerings and localizing their operations, indicating a shift towards more comprehensive engagement in the Chinese market [3][5] Group 1: Roche's Expansion - Roche has evolved from showcasing a few oncology drugs at the first CIIE to presenting over 40 products and solutions this year, covering the entire industry chain from early research to localized production [3] - The company has launched nearly 15 products in China over the past eight years, with a new biopharmaceutical base in Shanghai aimed at producing large molecule antibody drugs locally [3][5] Group 2: Gilead's Innovations - Gilead is actively advancing local research and development, currently conducting 16 projects in China, including 10 in oncology, with 90% of these projects synchronized with global timelines [5] - The company introduced Lenacapavir, the first long-acting HIV prevention drug requiring only two doses per year, marking a significant milestone in HIV prevention [2][5] Group 3: AstraZeneca's Investments - AstraZeneca signed a $136 million investment agreement for its Qingdao base during the expo, emphasizing China's role as its second-largest market and a source of innovation [3] - The company has invested over $1.7 billion in projects driven by previous CIIE events, embedding its production supply chain deeply into the Chinese market [3] Group 4: Merck and Eli Lilly's Contributions - Merck showcased its first HIF-2α inhibitor for VHL syndrome patients and announced plans to introduce over 40 new products and indications in the next five years [5] - Eli Lilly has invested over 20 billion RMB in China, establishing a comprehensive industry chain from research to commercialization, and plans to continue expanding its local collaborations [5][10] Group 5: Amway's Local Innovations - Amway introduced a vitamin and mineral powder product, the first "blue hat" multivitamin in China, reflecting its commitment to local research and development [6][10] - The company has established a plant research center in Wuxi and is integrating AI and traditional Chinese medicine to enhance its product offerings [8][10] Group 6: The Broader Impact of CIIE - The CIIE has become a platform for global companies to redefine their roles in China, with many establishing local R&D centers and committing to long-term investments [10][11] - The event is seen as a bridge for innovation and trust between China and the world, showcasing the potential for Chinese-developed products to reach global markets [11][12]